Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Ramy Rahmé · SciRah

Researcher profile · Semantic Scholar

Ramy Rahmé

Share profile

Ramy Rahmé — researcher profile on SciRah

h-index: 15
Works: 46
Citations: 1,093

Most-cited papers

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
T. Cluzeau, M. Sébert, Ramy Rahmé, S. Cuzzubbo +22 more
2021Journal of Clinical Oncology248 citations Open access
Semantic Scholar
Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
M. Sébert, M. Passet, A. Raimbault, Ramy Rahmé +15 more
2019Blood186 citations Open access
Semantic Scholar
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
N. Maslah, N. Salomao, L. Drevon, E. Verger +13 more
2019Haematologica123 citations Open access
Semantic Scholar
Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression
Ramy Rahmé, X. Thomas, C. Récher, N. Vey +17 more
2014Leukemia112 citations Open access
Semantic Scholar
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Edmond Chiche, Ramy Rahmé, S. Bertoli, P. Dumas +22 more
2021Blood Advances99 citations Open access
Semantic Scholar
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
T. Cluzeau, M. Sébert, Ramy Rahmé, S. Cuzzubbo +19 more
2019Blood70 citations
Semantic Scholar
FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias
Cécile Esnault, Ramy Rahmé, K. Rice, C. Berthier +5 more
2019Blood42 citations Open access
Semantic Scholar
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
D. Sallman, R. Komrokji, A. Dezern, M. Sébert +31 more
2021Blood30 citations
Semantic Scholar
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
S. Kayser, Ramy Rahmé, D. Martínez-Cuadrón, G. Ghiaur +19 more
2020Leukemia24 citations Open access
Semantic Scholar
Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
D. Sallman, R. Komrokji, A. Dezern, M. Sébert +29 more
2025HemaSphere22 citations Open access
Semantic Scholar
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
S. Kayser, R. Schlenk, D. Lebon, M. Carré +47 more
2021Haematologica22 citations Open access
Semantic Scholar
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy
M. Cerrano, M. Duchmann, R. Kim, Loic Vasseur +23 more
2020Leukemia22 citations Open access
Semantic Scholar
Assaying Cell Cycle Status Using Flow Cytometry.
Ramy Rahmé
2021Methods in molecular biology20 citations
Semantic Scholar
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
T. Cluzeau, F. Guolo, Edmond Chiche, P. Minetto +25 more
2024Blood Advances17 citations Open access
Semantic Scholar
Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report.
Ramy Rahmé, Emmanuel Benayoun, C. Pautas, C. Cordonnier +2 more
2013Experimental Hematology16 citations Open access
Semantic Scholar
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Ramy Rahmé, T. Braun, J. Manfredi, P. Fenaux
2023Biomedicines6 citations Open access
Semantic Scholar
Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
Ramy Rahmé, T. Braun
2024Journal of Clinical Medicine5 citations Open access
Semantic Scholar
CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort
Edmond Chiche, S. Bertoli, Ramy Rahmé, J. Micol +20 more
2019Blood5 citations Open access
Semantic Scholar
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)
Ramy Rahmé, L. Adès, X. Thomas, A. Guerci-Bresler +12 more
2018Haematologica4 citations Open access
Semantic Scholar
OncoAlert Round Table Discussions: The Global COVID-19 Experience
G. Morgan, E. de Azambuja, K. Punie, F. Ades +12 more
2021JCO Global Oncology3 citations Open access
Semantic Scholar
Prognostic Factors Influencing the Efficacy and Safety of Teclistamab and Elranatamab in Multiple Myeloma: A Multicenter Propensity-Weighted Analysis
J. Zerbit, G. Fouquet, Marion Detroit, Sylvain Choquet +14 more
2026JCO Oncology Advances2 citations Open access
Semantic Scholar
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis
T. Hueso, Grégory Lazarian, P. Chauvet, A. Chauchet +11 more
2025eJHaem2 citations Open access
Semantic Scholar
Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type
Ramy Rahmé, L. Resnick-Silverman, Vincent Anguiano, Moray J. Campbell +2 more
2025EMBO Reports2 citations Open access
Semantic Scholar
Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
T. Cluzeau, F. Guolo, Edmond Chiche, P. Minetto +26 more
2023Blood2 citations Open access
Semantic Scholar
Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience
Ramy Rahmé, V. Vidal, T. Hueso, L. Le-meur +6 more
2023Blood2 citations Open access
Semantic Scholar
Exome analysis of treatment-related AML after APL suggests secondary evolution
Tianjiao Wang, Meagan A. Jacoby, E. Duncavage, Christopher A. Miller +14 more
2018British Journal of Haematology2 citations Open access
Semantic Scholar
Plasmablastic Transformation of CLL/SLL: The Role of Early NGS Diagnosis and Targeted Multimodal Therapy
Jelena Filipović, Sara Milošević, Tatjana Terzic, Thorsten Braun +5 more
2026Diagnostics1 citations Open access
Semantic Scholar
Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.
J. Micol, R. Itzykson, L. Farnault, T. Cluzeau +19 more
2025Blood1 citations
Semantic Scholar
Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
R. Stammler, Peter Chen, O. Debeaupuis, Lin-Pierre Zhao +43 more
2025HemaSphere1 citations Open access
Semantic Scholar
Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)
M. Cerrano, M. Passet, Loic Vasseur, P. Hirsch +21 more
2019Blood1 citations Open access
Semantic Scholar
An update on treatment of higher risk myelodysplastic syndromes
Ramy Rahmé, L. Adès
2018Expert Review of Hematology1 citations
Semantic Scholar
Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort
M. Cerrano, M. Passet, Florence Rabian, Ramy Rahmé +18 more
2018Blood1 citations Open access
Semantic Scholar
Molecular Targets of Treatment in APL
Ramy Rahmé, Cécile Esnault
20181 citations
Semantic Scholar
Clinical and Molecular Characteristics of DDX41-Mutated Patients in a Large Cohort of Sporadic MDS/AML
M. Sébert, M. Passet, A. Raimbault, S. Quentin +10 more
2018Blood1 citations
Semantic Scholar
T‐Cell Acute Lymphoblastic Leukemia in a Young Patient With Andersen–Tawil Syndrome Successfully and Safely Treated With Intensive Chemotherapy Including Potential Precipitating Drugs: A Case Report After 3.5 Years of Follow‐up
Ramy Rahmé, Paule Moussounda Bamba, T. Do, A. Béhin +3 more
2026eJHaem0 citations Open access
Semantic Scholar
An unusual case of basophilic meningitis revealing a chronic-phase chronic myeloid leukemia: a report after almost three years of follow-up
Ramy Rahmé, M. Dragani, Carole Fleury, Giulia Tueur +8 more
2026Haematologica0 citations Open access
Semantic Scholar
Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study.
J. Zerbit, M. Vignon, G. Fouquet, Marion Detroit +15 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations Open access
Semantic Scholar
Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study
Ramy Rahmé, E. Raffoux, L. Adès, S. de Botton +33 more
2025Blood0 citations
Semantic Scholar
Prognosis of the IGLV3-21R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
Merieme Bensalah, A. Messaoudi, Carole Fleury, Giulia Tueur +13 more
2024Blood0 citations
Semantic Scholar
P961: BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS
T. Hueso, Ramy Rahmé, V. Vidal, S. Ivanoff +7 more
2023HemaSphere0 citations Open access
Semantic Scholar
Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
S. Kayser, Ramy Rahmé, D. Martínez-Cuadrón, G. Ghiaur +19 more
2021Leukemia0 citations Open access
Semantic Scholar
[Arsenic: The gold standard for acute promyelocytic leukaemia with FLT3-ITD mutation].
C. Esnault, Ramy Rahmé, H. de Thé
2021Medecine sciences : M/S0 citations Open access
Semantic Scholar
Management of APL in the Elderly
Ramy Rahmé, L. Adès, P. Fenaux
20180 citations
Semantic Scholar
Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide — an International Collaborative Study
S. Kayser, Ramy Rahmé, D. Martínez-Cuadrón, G. Ghiaur +19 more
2018Blood0 citations Open access
Semantic Scholar
Arsenic Overcomes Retinoic Acid-Resistance Conferred by FLT3-ITD in a Mouse Model of Acute Promyelocytic Leukemia (APL)
Ramy Rahmé, Cécile Esnault
20170 citations
Semantic Scholar
Study of missense mutant P53 activities in the murine hematopoietic system and leukaemic cells
Ramy Rahmé
0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Adès×23
Invite
L. Adès — researcher profile on SciRah
E. Raffoux×21
Invite
E. Raffoux — researcher profile on SciRah
P. Fenaux×18
Invite
P. Fenaux — researcher profile on SciRah
M. Sébert×11
Invite
M. Sébert — researcher profile on SciRah

×10

Invite

T. Cluzeau — researcher profile on SciRah

Invite

P. Peterlin — researcher profile on SciRah

Invite

X. Thomas — researcher profile on SciRah

Invite

C. Récher — researcher profile on SciRah

Invite

R. Itzykson — researcher profile on SciRah

Invite

J. Micol — researcher profile on SciRah

Invite

C. Berthon — researcher profile on SciRah

Invite

A. Pigneux — researcher profile on SciRah